possible explanation is that a subset of the aberrantly methylated loci harbors a common DNA binding motif, which is responsible for the binding of factors that promote aberrant methylation. A second plausible explanation is that an initiation event, such as uracil misincorporation or induced abasic sites, occurs in a particular genomic region followed by the spreading of methylation across sites in close proximity to the original initiation event. Based on our identification of methylation hot spots associated with ALL on chromosomes 19, 18 and 11, and with FL on chromosomes 19, 9 and 2, we believe that nuclear organization involving chromosome 19 may also play a role in aberrant methylation. Furthermore, the presence of clusters of aberrantly methylated loci in a region of chromosome 19 that is believed to harbor tumor suppressor genes and is known to harbor genes involved in DNA repair, together with the fact that the cells from which both ALL and FL are derived are subjected to DSBs, suggests that this region of chromosome 19 may harbor putative tumor suppressor genes associated with ALL and FL. Unfortunately, due to the limited genomic resolution of the microarray platform that was utilized and the dependence of our analysis on restriction enzyme recognition sequences, we view our findings to this point as preliminary discoveries that should lead to a full re-examination of the 'complete' methylome in ALL and NHL using more comprehensive assay technologies. If confirmed in a larger study, the potential impact of this finding is significant since it is possible that methylation is capable of spreading across chromosomal regions in close proximity and, as shown by others, epigenetic modifications such as this can lead to silencing of multiple genes in a coordinate fashion. These results are particularly interesting because chromosomes colocalize temporally in resting and activated B cells 7 and, in some instances, nuclear architecture is thought to affect a number of processes including epigenetic mechanisms. 8 This argument suggests that the physical proximity of specific chromosomal regions within the nucleus at key points during the cell cycle (or neoplastic transformation) might facilitate the initiation and spreading of methylation and gene silencing.
Non-specific amplification of patient-specific Ig/TCR gene rearrangements depends on the time point during therapy: implications for minimal residual disease monitoring Several studies have shown that detection of minimal residual disease (MRD) has prognostic relevance in childhood and adult acute lymphoblastic leukemia (ALL), both at initial diagnosis, at relapse, and before stem cell transplantation. Consequently, MRDbased therapy stratification nowadays is being included in many ALL treatment protocols. In most clinical ALL studies, MRD is being evaluated by real-time quantitative PCR (RQ-PCR) analysis of immunoglobulin (Ig) and T-cell receptor (TCR) gene rearrangements, which serve as patient-specific markers for the leukemic cells.
Recently, the European Study Group on MRD detection in ALL developed guidelines for the interpretation of RQ-PCR data, 1 which are crucial for multi-center MRD studies. 2 These guidelines include a definition of the 'Quantitative Range' (the reproducible part of the assay in which data can accurately and reliably be quantified) and definitions of MRD positivity. In these definitions, the presence and level of non-specific amplification (NSA) plays an important role. NSA is dependent on the Ig/TCR locus involved, the gene segments used and the number and type of deleted and inserted nucleotides in the junctional region. For example, NSA occurs in about 35% of IGH targets (particularly those using the JH4, JH5 or JH6 gene segment) and in over 90% of TCRG targets.
should be at least three cycles apart from the lowest C T value of the NSA observed in normal PB buffy coat DNA, that is, even an eightfold increase in the level of NSA should not affect the Quantitative Range of the assay.
1 Furthermore, to be considered positive, the C T value of a sample has to have a minimum distance from the NSA. Within the ESG-MRD-ALL, two sets of guidelines were designed for analysis of follow-up samples. 1 The first set of guidelines aims at the prevention of false-negative results (a sample being considered MRD-positive if the C T value of at least one of the three replicates is X1.0 C T lower than the lowest C T of background), whereas the second set of guidelines aims at prevention of false-positive results (a sample being considered MRD-positive if the C T value of at least one of the three replicates is X3.0 C T lower than the lowest C T of background). 1 However, it is unknown whether these guidelines indeed appropriately take into account variations in NSA. We therefore evaluated the variations in NSA during and after different phases of therapy and analyzed the impact of such variation on the interpretation of MRD data.
We selected seven IGH targets (five with some NSA, two without any NSA) and five TCRG targets (all with some NSA) as representative Ig and TCR targets, respectively. NSA was determined by analysis of six wells with DNA obtained from a pool of PB buffy coats obtained from ten healthy donors. The twelve patient-specific targets were evaluated on bone marrow samples obtained from five other ('non-related') ALL patients (all in complete remission) during and after therapy according to the DCOG-ALL-8 protocol. 7 Generally, from each patient twelve bone marrow samples were evaluated, resulting in a total of 718 analyzed samples. RQ-PCR data were subsequently interpreted according to the two sets of guidelines of the ESG-MRD-ALL, that is, the prevention of false positive and false negative RQ-PCR results. 1 For IGH targets with NSA, the level of NSA differed significantly between various follow-up samples of patients and in many follow-up samples the NSA differed from the one observed in normal PB buffy coat DNA (see example in Figure 1a ). Analysis of IGH targets without NSA showed that generally no NSA was observed in follow-up samples of other ALL patients (that is, patients lacking the patient-specific rearrangements). For TCRG targets, which all showed some level of NSA, the level of NSA observed in follow-up samples of different patients was generally comparable to or lower than normal PB buffy coat DNA (see example in Figure 1b) . These data show that NSA can be variable, dependent on the type of sample (bone marrow or peripheral blood) and the time point during or after therapy.
We next evaluated to what extent this variation in NSA affected the RQ-PCR data interpretation, applying the guidelines for prevention of false-positive MRD results as well as the guidelines for preventing false-negative MRD results. In Figures  2a-c , the data interpreted according to the guidelines for the prevention of false-negative MRD results are shown. IGH targets with NSA in normal PB buffy coat DNA resulted in false-positive MRD data in about 10% of samples obtained during therapy (Figure 2a) . However, in samples obtained after cessation of therapy (after week 104) false-positivity could be observed in up to 65% of samples. In one sample the level of NSA even reached the Quantitative Range of the assay (Figure 2a) . False-positive MRD results were hardly observed for IGH targets without NSA in normal PB buffy coat DNA (Figure 2b ) and were less than 10% for TCRG targets, irrespective of the time-point the sample was taken (Figure 2c) . If the guidelines for prevention of falsepositive MRD results were applied, false-positivity was only observed for IGH targets that also showed NSA in normal PB buffy coat DNA (Figures 2d and e) . This false-positivity was present only in a few samples obtained after induction therapy (o5%) and in some samples obtained after cessation of therapy (5-15%).
Our data are in line with the previously reported changes in the cellular composition of the bone marrow during and after therapy (Figures 1c and d) . [4] [5] [6] After induction therapy, there is a massive regeneration of precursor B cells, particularly the most immature CD10
þ TdT þ precursor B cells, 4, 5 which have incomplete IGH (D H -J H ) rearrangements but low levels complete IGH (V H -J H ) gene rearrangements. 8 In contrast, after cessation of maintenance therapy the precursor B cell compartment in bone marrow mainly consists of more mature CD10 þ TdT À precursor B cells 4, 5 containing complete IGH gene rearrangements. 8 Consequently, increased NSA levels of IGH (V H -J H ) rearrangements can particularly be observed during the post-maintenance treatment regeneration phases. T cells show limited changes in their frequency in bone marrow samples; they are particularly present in bone marrow samples taken during induction therapy and are present at low frequencies during other stages of therapy. 6 In fact, the percentage of T cells in PB buffy coats obtained from healthy individuals will be significantly higher than in most bone marrow samples. Consequently, the NSA of TCRG gene rearrangements observed in bone marrow samples generally is lower than that observed in normal PB buffy coat DNA and limited variations in the number of T cells present in bone marrow will not have any impact on RQ-PCR data interpretation. Since the NSA for TCRG will be higher in PB buffy coat (as generally used for defining the Quantitative Range) than in bone marrow (used for MRD evaluation), the actual Quantitative Range for TCRG targets will often be underestimated.
We conclude that the ESG-MRD-ALL guidelines for interpretation of RQ-PCR data appropriately take into account the variation in NSA. The guidelines for prevention of false-positive MRD data perform well, with less than 2% false-positive results. However, our data also clearly indicate that positive results outside the Quantitative Range should always be judged with caution, particularly for samples taken after cessation of therapy and analyzed with Ig gene targets. Preferably, one should aim for RQ-PCR assays without any NSA, since this will improve the reliability of the data interpretation.
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